my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
21-07-2011: BioFocus and InterMed Discovery GmbH (IMD) announced a marketing collaboration to offer enhanced natural product discovery to the pharmaceutical, animal health, and agrochemical industries. No financial details were disclosed.
Under the terms of the collaboration, IMD will make its natural product screening libraries available and provide follow-on services to BioFocus. BioFocus will then incorporate these as part of its own integrated drug discovery offerings. BioFocus has a track record of service deals with industry for the discovery of active ingredients in pharmaceutical, animal health and agrochemical applications.
“We believe that the combination of our natural product capabilities with the well known discovery capabilities of BioFocus will offer a powerful discovery solution at a time when there is already growing demand from the pharma, veterinary and agro industries to fill depleted pipelines,“ said Dr. Thomas Henkel, co-Managing Director of InterMed Discovery.
“We have been impressed with the scale of IMDs natural product discovery capabilities and we believe that when InterMed’s natural product libraries and services are combined with our screening services, our engine for drug discovery will be substantially enhanced and more cost-effective for our clients,” added Dr. Chris Newton, Managing Director, BioFocus.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Galapagos subsidiary BioFocus and Ono sign a drug discovery agreement in the Field of CNS Disorders
Galapagos NV announced that its service division BioFocus and Ono Pharmaceutical Co., Ltd. have signed a new collaboration agreement, focused on discovering novel drugs in the field of CNS disorders. Under the new agreement, BioFocus will use its drug discovery platform to deliver leads an ... more
Galapagos’ service companies, BioFocus and Argenta, announced they have entered into a multi-year collaboration agreement with AstraZeneca to find new compounds against key targets of interest to AstraZeneca’s research programs in respiratory and inflammatory diseases. Under the terms of th ... more
Almirall and BioFocus enter research alliance
Almirall, S.A. announced that it has formed a research alliance with BioFocus, an affiliate from Galapagos NV.The three-year alliance is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall. Under the terms of the collaboration, BioFo ... more
As the service division of Galapagos, BioFocus DPI offers a full suite of target-to-drug discovery products and services. Our aim is to expand our partners’ drug pipeline by accelerating the gene-to-candidate discovery process. We achieve this by offering a biologically-focused discovery ... more
We are a genomics based drug discovery company, that has drug discovery programs based on proprietary disease modifying drug targets. Our vision is to bring novel drugs to the market in selected diseases areas for which there is a need for effective and safe medicines. We focus on developin ... more
BioFocus and InterMed Discovery Announce Marketing Collaboration
BioFocus and InterMed Discovery GmbH (IMD) announced a marketing collaboration to offer enhanced natural product discovery to the pharmaceutical, animal health, and agrochemical industries. No financial details were disclosed. Under the terms of the collaboration, IMD will make its natural ... more
Cognis and InterMed Discovery (IMD) are continuing their strategic cooperation: Cognis has now exclusively licensed two new active ingredients for weight management and cognitive performance from IMD, further expanding the company’s innovation pipeline. Tests on the products Cognis has alre ... more
InterMed Discovery Receives Michael J. Fox Foundation Award for IMD-026259
InterMed Discovery (IMD) announced that it has received an award from The Michael J. Fox Foundation for Parkinson’s Research for its programme to develop IMD-026259 as a pharmaceutical treatment to challenge neuro-degeneration in Parkinson’s disease (PD). PD is a disease of progressive neu ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
